home

LATEST ONCOPRESCRIBE UPDATES

• Updated Overall Survival with KISQALI® plus FASLODEX® in Advanced Breast Cancer

• Infection Risk in Multiple Myeloma Patients Receiving New Generation Therapies

• Real-world evidence: What can it inform us about the second-line treatment of metastatic squamous NSCLC?

• Maintenance RUBRACA® in Patients with Advanced Pancreatic Cancer with a Pathogenic Germline or Somatic Variant in BRCA1, BRCA2, or PALB2

SHOW MORE

FDA
Approvals

Meeting
Updates

Hem/Onc
Updates

Symptom
Management

NEW REGIMENS ADDED

Research Regimens

• Single Agent PEMAZYRE® - for Cholangiocarcinoma

• PARAPLATIN® and VEPESID® with IMFINZI® - for Small Cell Lung Cancer

• IMFINZI® Maintenance - Small Cell Lung Cancer

• TECENTRIQ® and ABRAXANE® - for Breast Cancer

• IDHIFA® - for Acute Myeloid Leukemia

Curbside Consultation

Lung Cancer Special Issue

Immuno-Oncology

Precision Oncology

• COVID-19 Associated Coagulopathy: Diagnosis and Management

• Dual Inhibition Improves Outcomes for Patients with BRAF-Mutated Colorectal Tumors

• Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening

• FDA Approves ENDARI®, A New Treatment for Sickle Cell Disease

SHOW MORE